作者:Christoph T. Behrendt、Andrea Kunfermann、Victoria Illarionova、An Matheeussen、Miriam K. Pein、Tobias Gräwert、Johannes Kaiser、Adelbert Bacher、Wolfgang Eisenreich、Boris Illarionov、Markus Fischer、Louis Maes、Michael Groll、Thomas Kurz
DOI:10.1021/jm200694q
日期:2011.10.13
Reverse hydroxamate-based inhibitors of IspC, a key enzyme of the non-mevalonate pathway of isoprenoid biosynthesis and a validated antimalarial target, were synthesized and biologically evaluated. The binding mode of one derivative in complex with EcIspC and a divalent metal ion was clarified by X-ray analysis. Pilot experiments have demonstrated in vivo potential.
合成了IspC的基于异羟肟酸的反向抑制剂,该抑制剂是类异戊二烯生物合成的非甲羟戊酸途径的关键酶,并且是经过验证的抗疟靶,并对其进行了生物学评估。通过X射线分析阐明了一种衍生物与Ec IspC和二价金属离子复合的结合方式。初步实验证明了体内潜力。